stockrow
Friday 6 November 2026
Export TRVI’s income statement to Excel — free account
Trevi Therapeutics, Inc.
TRVI Healthcare Biotechnology
- EPS
- −22.2%
- Free cash flow
- −73.8%
Quarter to June 2026, against a year earlier
14.22
1.41
+11.01%
Follow TRVI
Alert me
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
0.41 | 3.11 | 3.30 | 11.45 | 8.33 | 2.98 | 9.15 | 15.03 | 10.41 | 19.66 |
Net Debt/EBITDA |
(1.60) | 2.77 | 0.33 | 2.14 | 0.95 | 0.70 | 3.79 | 2.47 | 2.09 | 3.83 |
Debt/Assets |
262.94% | 23.78% | 10.41% | 0.59% | 30.26% | 37.65% | 7.44% | 0.03% | 0.00% | 0.00% |
Debt/Equity |
(1.27) | 0.36 | 0.18 | 0.01 | 0.52 | 0.85 | 0.09 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
1.67 | 0.64 | 0.72 | 0.86 | 0.89 | 0.85 | 0.97 | 1.09 | 0.80 | 0.98 |
Capex/Depreciation |
0.00 | (0.01) | (1.90) | (0.23) | (0.12) | 0.00 | (0.28) | (0.45) | (0.24) | (0.08) |
Interest Coverage |
(6.61) | (2.46) | (105.79) | (33.64) | (71.25) | (27.02) | (25.72) | (86.76) | (12,881.00) | — |
| 8.58% | 16.02% | 26.38% | 97.38% | (80.07%) | (153.03%) | (46.82%) | (30.59%) | (52.59%) | (30.23%) | |
| (43.83%) | (81.86%) | (156.18%) | (75.87%) | (61.15%) | (79.29%) | (36.10%) | (27.37%) | (47.84%) | (28.10%) | |
ROIC |
0.00% | 0.00% | (8,102.11%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
55.97% | (83.32%) | (406.18%) | (49.12%) | (80.26%) | (134.22%) | (26.65%) | (35.47%) | (48.36%) | (23.48%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(0.69) | (18.97) | (42.12) | (1.97) | (1.61) | (1.27) | (0.44) | (0.32) | (0.38) | (0.31) |
Cash per Share |
0.51 | 52.30 | 16.44 | 4.88 | 2.49 | 1.61 | 1.87 | 0.84 | 1.06 | 1.40 |
Shareholders Equity per Share |
(1.08) | 35.10 | 14.26 | 4.65 | 1.51 | 0.75 | 1.66 | 0.83 | 0.98 | 1.36 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(1.08) | 35.10 | 14.26 | 4.65 | 1.51 | 0.75 | 1.66 | 0.83 | 0.98 | 1.36 |
Free Cash Flow |
(11.19) | (7.99) | (18.45) | (23.10) | (29.03) | (28.95) | (28.33) | (31.85) | (38.29) | (42.10) |
Working Capital |
(12.00) | 15.04 | 6.15 | 54.35 | 40.71 | 25.23 | 109.22 | 81.72 | 98.92 | 181.91 |
Capital Expenditures |
— | (0.01) | (0.16) | (0.01) | (0.03) | — | (0.16) | (0.14) | (0.03) | (0.01) |
Net Current Asset Value |
(17.43) | 14.71 | 4.55 | 54.10 | 26.42 | 16.56 | 107.06 | 80.69 | 98.17 | 181.46 |
| Other line items | ||||||||||
Quick Ratio |
0.41 | 3.10 | 2.76 | 11.13 | 8.10 | 2.89 | 8.99 | 14.25 | 10.24 | 19.31 |
Depreciation/Fixed assets |
0.80 | 156.07 | 0.56 | 0.33 | 2.66 | 12.25 | 3.31 | 1.40 | 0.94 | 0.81 |
Cash ROIC |
(86.18%) | (18.98%) | (126.82%) | (20.59%) | (33.55%) | (42.32%) | (11.95%) | (19.24%) | (18.47%) | (11.33%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Accounts Payable Turnover |
0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
40,606.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.69) | (18.94) | (41.76) | (1.97) | (1.61) | (1.27) | (0.44) | (0.32) | (0.38) | (0.31) |
Capex per Share |
0.00 | (0.03) | (0.36) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
0.03 | 0.03 | 0.12 | 0.37 | 0.41 | — | — | — | — | — |
Average Payables |
0.49 | 0.49 | 0.57 | 1.10 | 1.81 | 2.43 | 2.85 | 2.33 | 2.61 | 3.66 |
Average Assets |
15.32 | 15.32 | 16.38 | 35.26 | 53.57 | 42.80 | 80.75 | 106.21 | 100.15 | 152.17 |
Average Common Equity |
(78.29) | (78.29) | (96.96) | (27.47) | 40.91 | 22.18 | 62.27 | 95.00 | 91.10 | 141.44 |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 25 Oct 2026